IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn’s Disease
Stephen B. Hanauer(Northwestern University), Subrata Ghosh(University College Cork), Bruce E. Sands(Icahn School of Medicine at Mount Sinai), William J. Sandborn(University of San Diego), Brian G. Feagan(Western University), Bin Zou(Third Affiliated Hospital of Guangzhou Medical University), Paul Rutgeerts(KU Leuven), Jean–Frédéric Colombel(Icahn School of Medicine at Mount Sinai), Willem J.S. de Villiers(Stellenbosch University), Omoniyi J. Adedokun(Western University), Jewel Johanns(Johnson & Johnson (United States)), Christopher Gasink(Janssen (United States))
Cited by 211
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k